ArticleCancer management and research2019

Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study.

Yu-Hung Fang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.